To study the oxytocic effect of trypsin, we measured the force of isom
etric contraction in uteri isolated from estrogenized rats exposed to
trypsin (8.8x10(-10) to 1.7x10(-6) mol/L) either alone or in the prese
nce of receptor antagonists to angiotensin II [saralasin ([Sar(1),Ala(
8)]angiotensin II) or DuP 753 (losartan)] or to kinins (D-[Arg(9),Hyp(
3),Thi(5,8),D-Phe(7)]bradykinin). We found that saralasin or DuP 753,
but not the kinin antagonist, displaced the dose-response curve to the
right. Exposure to exogenous angiotensin I desensitized the preparati
on to further doses of either angiotensin I or II or trypsin, without
altering the effects of oxytocin or bradykinin. Enalaprilat (an angiot
ensin I converting enzyme inhibitor) or pepstatin A (a renin inhibitor
) also displaced the dose-response curve to trypsin to the right, with
out altering the effects of oxytocin or angiotensin II. Our results in
dicate that the response to trypsin is mediated by an agent produced f
rom a substrate present in the uterus and acting on the angiotensin II
type 1 receptor and are consistent with both renin and angiotensin I
converting enzyme being involved in its mechanism of action, thus supp
orting the notions that the renin-angiotensin system may be important
in the late stages of pregnancy and that serine proteases existing in
the uterus may contribute to its activation.